Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT02130817 · University of Wisconsin, Madison · PHASE4 · withdrawn · last registry update 2018-12-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Organ transplant criteria made recruitment difficult. Closed with IRB 10/09/2015.” | – | Registry record, University of Wisconsin, Madison |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-11-22Also stopped (terminated): Johns Hopkins University, Abatacept Injection (NCT03059888)
- 2019-09-10Results posted on the registry: Columbia University, Belatacept + Tacrolimus (NCT02152345)
- 2019-07-10Phase 3 first posted: Nantes University Hospital, Belatacept 250 Milligram Intravenous Powder for Solution (NCT04013620)
- 2019-06-27Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Preparative regimen (NCT04000698)
- 2019-06-18Results posted on the registry: Dinesh Khanna, MD, MS, Abatacept + Placebo (NCT02161406)
- 2019-05-02Also stopped (withdrawn): Duke University, Belatacept + Carfilzomib (NCT03805178)
- 2019-04-17Results posted on the registry: Columbia University, Abatacept (NCT02018042)
- 2019-04-17Results posted on the registry: Bristol-Myers Squibb, Process E Belatacept + Process C Belatacept (NCT02564497)
- 2019-04-08Results posted on the registry: Bristol-Myers Squibb, Abatacept + Methotrexate (NCT02504268)
- 2019-02-21Results posted on the registry: Oregon Health and Science University, Abatacept (NCT01279954)
- 2019-02-15Phase 3 first posted: Duke University, Abatacept Injection (NCT03841357)
- 2018-12-26Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Ustekinumab + Abatacept (NCT01999868)
- 2018-08-15Phase 3 first posted: University Hospital, Brest, Abatacept + Placebos (NCT03632187)
- 2018-02-26Results posted on the registry: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Abatacept + Placebo (NCT00556439)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2017-12-21Results posted on the registry: Bristol-Myers Squibb, BMS-188667 + Mycophenolate mofetil (NCT01714817)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision